Evidence map›Paper›PMID 38504364›Full record

ArticleThe journal of pathology. Clinical research2024

A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.

Miriam Angeloni, Thomas van Doeveren, Sebastian Lindner, Patrick Volland, Jorina Schmelmer, Sebastian Foersch, Christian Matek, Robert Stoehr, Carol I Geppert, Hendrik Heers and 11 more

Open access · goldAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Miriam AngeloniInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.ORCID 0000-0003-2105-6305
Thomas van DoeverenDepartment of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands.
Sebastian LindnerInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Patrick VollandInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Jorina SchmelmerInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Sebastian FoerschInstitute of Pathology, University Medical Center Mainz, Mainz, Germany.
Christian MatekInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Robert StoehrInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Carol I GeppertInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Hendrik HeersDepartment of Urology, Philipps-Universität Marburg, Marburg, Germany.
Sven WachComprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Helge TaubertComprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Danijel SikicComprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bernd WullichComprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Geert Jlh van LeendersDepartment of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
Vasily ZaburdaevDepartment of Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Markus EcksteinInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Arndt HartmannInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Joost L BoormansDepartment of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands.
Fulvia FerrazziInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.ORCID 0000-0003-4011-4638
Veronika BahlingerInstitute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.ORCID 0000-0001-5919-7651
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEErasmus MC Cancer Institute · NLJohannes Gutenberg University Mainz · DEPhilipps University of Marburg · DE

Funding

Bayerisches Zentrum für KrebsforschungBundesministerium für Bildung und Forschung 01KD2211BDeutsche Forschungsgemeinschaft 493665037Deutsche Forschungsgemeinschaft TRR305 (projectsZ01andZ02)Deutsche Forschungsgemeinschaft TRR374 (projectINF)Else Kröner-Fresenius-Stiftung 2020_EKEA.129Interdisziplinäre Zentrum für Klinische Forschung FAU Erlangen-NürnbergKWF Kankerbestrijding
6 · The paper itself

Abstract

Upper tract urothelial carcinoma (UTUC) is a rare and aggressive, yet understudied, urothelial carcinoma (UC). The more frequent UC of the bladder comprises several molecular subtypes, associated with different targeted therapies and overlapping with protein-based subtypes. However, if and how these findings extend to UTUC remains unclear. Artificial intelligence-based approaches could help elucidate UTUC's biology and extend access to targeted treatments to a wider patient audience. Here, UTUC protein-based subtypes were identified, and a deep-learning (DL) workflow was developed to predict them directly from routine histopathological H&E slides. Protein-based subtypes in a retrospective cohort of 163 invasive tumors were assigned by hierarchical clustering of the immunohistochemical expression of three luminal (FOXA1, GATA3, and CK20) and three basal (CD44, CK5, and CK14) markers. Cluster analysis identified distinctive luminal (N = 80) and basal (N = 42) subtypes. The luminal subtype mostly included pushing, papillary tumors, whereas the basal subtype diffusely infiltrating, non-papillary tumors. DL model building relied on a transfer-learning approach by fine-tuning a pre-trained ResNet50. Classification performance was measured via three-fold repeated cross-validation. A mean area under the receiver operating characteristic curve of 0.83 (95% CI: 0.67-0.99), 0.8 (95% CI: 0.62-0.99), and 0.81 (95% CI: 0.65-0.96) was reached in the three repetitions. High-confidence DL-based predicted subtypes showed significant associations (p < 0.001) with morphological features, i.e. tumor type, histological subtypes, and infiltration type. Furthermore, a significant association was found with programmed cell death ligand 1 (PD-L1) combined positive score (p < 0.001) and FGFR3 mutational status (p = 0.002), with high-confidence basal predictions containing a higher proportion of PD-L1 positive samples and high-confidence luminal predictions a higher proportion of FGFR3-mutated samples. Testing of the DL model on an independent cohort highlighted the importance to accommodate histological subtypes. Taken together, our DL workflow can predict protein-based UTUC subtypes, associated with the presence of targetable alterations, directly from H&E slides.

Indexed as

Carcinoma, Transitional CellDeep LearningUrinary Bladder NeoplasmsUrologic NeoplasmsArtificial IntelligenceB7-H1 AntigenBiomarkers, TumorHumansMolecular Diagnostic TechniquesRetrospective StudiesWorkflowB7-H1 AntigenBiomarkers, Tumordeep-learningdigital pathologyimmunohistochemistryprotein-based subtypestargeted therapyupper tract urothelial carcinomawhole slide images

Identifiers

PMID38504364
PMCPMC10951050
OpenAlexW4393015849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.